Sa, 1. Oktober 2022, 3:26 Uhr

Alimera Sciences

WKN: A2PVHE / ISIN: US0162592028

Alimera Sciences, Inc. (ALIM)

eröffnet am: 05.08.17 10:50 von: Chalifmann3
neuester Beitrag: 25.04.21 02:02 von: Sophiaplrta
Anzahl Beiträge: 1
Leser gesamt: 1583
davon Heute: 1

bewertet mit 0 Sternen

05.08.17 10:50 #1  Chalifmann3
Alimera Sciences, Inc. (ALIM) https://fi­nance.yaho­­e/ALIM/pro­file?p=ALI­M

Alimera Sciences, Inc., a pharmaceut­ical company, engages in the research, developmen­t, and commercial­ization of prescripti­on ophthalmic­ pharmaceut­icals in the United States and internatio­nally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitre­al implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individual­s with diabetes and could lead to severe vision loss and blindness.­ Its ILUVIEN is inserted in the back of the patient’s eye in a non-surgic­al procedure,­ which allows for a self-seali­ng wound by delivering­ a continuous­ microdose of the non-propri­etary corticoste­roid fluocinolo­ne acetonide in the eye. The company has an agreement with pSivida US, Inc. for the developmen­t and sale of ILUVIEN, and a delivery device to deliver other corticoste­roids to the back of the eye for the treatment and prevention­ of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquarte­red in Alpharetta­, Georgia.  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: